Invited Speaker | Meeting the Challenge Summit: Diversity in Dermatology Clinical Trials
David Rubenstein, MD, PhD, FAAD currently serves as Chief Scientific Officer for Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dr. Rubenstein joined Dermavant in March 2018 from GlaxoSmithKline Dermatology where he had built an industry-leading dermatology drug development organization as Vice President, Discovery and Preclinical Development. Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology. He is a board-certified dermatologist.
Click here for more information on the Valeant Research Award.
Read published peer-reviewed articles written your by Skin of Color Society members
Did You Know
Skin of color patients comprise the majority in California, New Mexico and Texas…and soon will be the majority in Arizona, Nevada, Georgia, New York and Florida.
By 2042, more than 50% of the US population will have skin of color.